STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO) (STEREO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01300299|
Recruitment Status : Withdrawn (Unable to enroll)
First Posted : February 21, 2011
Last Update Posted : March 5, 2018
|Condition or disease||Intervention/treatment|
|Non-small Cell Lung Cancer (NSCLC)||Radiation: Stereotactic Body Radiation Therapy|
This study evaluates the effect of adjuvant chemotherapy in patients who received treatment with stereotactic radiation for early stage lung cancer and who are at high risk for microscopic metastatic disease.
Chemotherapy in the form of cisplatin/docetaxel or cisplatin/pemetrexed will be administered approximately six weeks after Stereotactic Body Radiation Therapy (SBRT). Patients will then undergo follow up clinical evaluation and imaging to evaluate treatment response and for surveillance.
A patient population of 65 patients will be required. Enrollment in this protocol is planned by multi center involvement in the state of Kentucky as part of the Kentucky Trial Network (KTN).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)|
|Study Start Date :||February 2011|
|Primary Completion Date :||February 2015|
|Study Completion Date :||February 2015|
Experimental: All subjects
Subjects will receive chemotherapy after stereotactic body radiation therapy.
Radiation: Stereotactic Body Radiation Therapy
12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within <2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
- To measure the feasibility of adjuvant chemotherapy after stereotactic body radiation therapy for early stage non-small cell lung cancer (NSCLC) [ Time Frame: 3 years after subject enrollment ]
- Survival rate, specifically disease-free survival (DFS) and overall survival (OS), measured by follow-up visits and tests [ Time Frame: 3 years after subject enrollment ]
- safety of adjuvant chemotherapy after stereotactic body radiation therapy for early stage non-small cell lung cancer (NSCLC) measured by adverse events [ Time Frame: 3 years after subject enrollment ]
- quality of life (QOL) measured by subject questionnaires [ Time Frame: 3 years after subject enrollment ]
- Measurement of biological and clinical markers for toxicity, DFS, and OS [ Time Frame: 3 years after subject enrollment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01300299
|United States, Kentucky|
|James Graham Brown Cancer Center|
|Louisville, Kentucky, United States, 40202|
|Principal Investigator:||Goetz H Kloecker, MD||James Graham Brown Cancer Center|